A white color round tablet one side is impressed with a score and the other side with "C", "
Click on icon to see table/diagram/image".
Each tablet contains: Cinnarizine 25 mg.
Anti-Vertigo.
Pharmacology: Pharmacodynamics: Cinnarizine increases and normalizes cerebral circulation and thereby increase the oxygen supply of the arteriosclerotic cerebral vessels. It prevents and eliminates vascular spasms of the labyrinth.
The improvement of cerebral circulation is also sustained by the fact that Cinnarizine increases the blood flow as well as the blood and oxygen supply to the heart muscle. The heart capacity is improved.
The mechanism of action of Cinnarizine may be explained by its direct inhibitory action on the tonus of the smooth muscles of certain arterioles which renders less sensitive to certain contractile substances such as angiotensin.
Pharmacokinetics: In animals, cinnarizine is extensively metabolised, N-dealkylation being the major pathway. Approximately two thirds of the metabolites are excreted with faeces, the rest in the urine, mainly during the first five days after a single dose.
Absorption: In man, after oral administration, absorption is relatively slow, peak serum concentration occurring after 2.5 to 4 hours.
Distribution: The plasma protein binding of cinnarizine is 91%.
Metabolism: Cinnarizine is extensively metabolized mainly via CYP2D6, but there is considerable interindividual variation in the extent of metabolism.
Elimination: The reported elimination half-life for cinnarizine ranges from 4 to 24 hours.
The elimination of metabolites occurs as follows: one third in the urine (unchanged as metabolite and glucuronide conjugates) and two thirds in the faeces.
For the symptomatic treatment of nausea and vertigo caused by Meniere's disease and other vestibular disorders, and for the prevention and treatment of motion sickness. Also used in the management of various peripheral and cerebral vascular disorders.
Adult dose is 1 tablet three times daily after meal.
Children aged 5 to 12 years may be given half the adult dose.
For motion sickness: 1 tablet may be given 2 hours before the start of the journey and 1/2 tablet every 8 hours during the journey. Or as prescribed by a physician.
Symptoms: The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine.
Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. Vomiting, alterations in consciousness ranging from somnolence to stupor and coma. Extrapyramidal symptoms and hypotonia are the most commonly reported signs and symptoms associated with a cinnarizine overdose. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdose involving cinnarizine.
Treatment: There is no specific antidote to cinnarizine and in the event of overdosage, treatment is symptomatic and supportive care. The administration of activated charcoal should only be considered in patients presenting within one hour of taking a potentially toxic overdose (i.e., more than 15 mg/kg).
High doses of cinnarizine should be used with caution in patients with hypotension because of the possibility of decreasing the blood pressure further.
May cause drowsiness, patients affected in this way should not drive or operate machinery.
Use in Pregnancy: It is not advisable to administer in pregnant women.
Pregnancy: The safety of cinnarizine in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs, it is not advisable to administer cinnarizine in pregnancy.
Breast-feeding: There are no data on the excretion of cinnarizine on human breast milk. Taking cinnarizine whilst breast-feeding is not recommended.
Only high doses may occasionally cause a slight sleepiness which disappears rapidly after reducing the dose. Other side effects are skin allergic reaction and fatigue.
Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of these drugs or of cinnarizine.
Cinnarizine may present an otherwise positive reaction to dermal reactivity if used within 4 days prior to skin testing as it is an antihistamine.
Store at temperatures not exceeding 30°C. Protect from light.
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Verziron tab 25 mg
100's (P36/tab, P3,600/box)
Sign Out
Click on icon to see table/diagram/image
